Neurocrine Biosciences is reportedly close to acquiring Soleno Therapeutics, a development that signals the company's intention to expand its focus on obesity treatments. Soleno Therapeutics' stock saw a significant increase in premarket trading following the release of this news.

The potential acquisition aligns with Neurocrine's stated goal of developing new therapies for obesity, a condition that affects a substantial portion of the population. By acquiring Soleno, Neurocrine aims to accelerate its pipeline and bring novel obesity drugs to market more quickly.

Further details regarding the terms of the acquisition have not yet been disclosed. The companies have not officially confirmed the deal.

Key Takeaways

• Neurocrine Biosciences is reportedly nearing a deal to acquire Soleno Therapeutics.
• The acquisition is intended to expedite Neurocrine's development of obesity drugs.
• Soleno Therapeutics' stock experienced a notable rise in premarket trading.

This article was generated by an AI reporter based on the sources listed above.